Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

IMPORTANCE Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease.

Elmentve itt :
Bibliográfiai részletek
Szerzők: Rosenstock Julio
Perkovic Vlado
Johansen Odd Erik
Cooper Mark E.
Kahn Steven E.
Kollaborációs szervezet: CARMELINA Investigators
Mihály Emese
Keltai Katalin
Baló Tímea
Somogyi Anikó
Nagy Géza
Tabák Ádám
Ferencz Viktória
Domján Beatrix Annamária
Tänczer Tímea
Bajnok László Zoltán
Szujó Szabina
Nemes Orsolya
Mezősi Emese
Bódis Beáta
Márton Zsolt
Takács Róbert
Ábrahám György
Fehértemplomi Katalin
et al
Dokumentumtípus: Cikk
Megjelent: 2019
Sorozat:JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 321 No. 1
Tárgyszavak:
Klinikai orvostan
doi:10.1001/jama.2018.18269

mtmt:30470479
Online Access:http://publicatio.bibl.u-szeged.hu/27237
Leíró adatok
Tartalmi kivonat:IMPORTANCE Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease.
Terjedelem/Fizikai jellemzők:69-79
ISSN:0098-7484

Hasonló tételek